1. Analyst View
2. Research Overview
3. Biotechnology Industry Overview
3.1 Biotechnology Industry - Worldwide
3.2 Biotechnology Industry - Asia-Pacific
3.3 Biotechnology Industry - India
4. Indian Biotechnology Industry Performance
4.1 Market Size
4.2 Biotech Domestic and Exports Market
4.3 Biotech Market Segmentation
4.3.1 Biopharmaceuticals
4.3.1.1 Vaccines
4.3.1.2 Therapeutics
4.3.1.3 Diagnostics
4.3.1.4 Other Biogenerics
4.3.1.4.1 Stem Cell Research
4.3.2 BioServices (Contract Research)
4.3.3 Agri Biotech
4.3.3.1 Biofertilisers and BioPesticides
4.3.4 Industrial Biotech
4.3.5 Bioinformatics
4.4 Biotech Parks
4.4.1 Shapoorji Pallonji Biotech Park
4.4.2 ICICI Knowledge Park
4.4.3 International Biotech Park
4.4.4 Lucknow Biotech Park
4.4.5 Ticel Bio Park
4.4.6 Upcoming Parks
4.5 Investments in Indian Biotechnology Sector
4.6 Employment Opportunities in Biotech Sector
4.7 National Biotechnology Development Strategy
5. Indian Bio-Clusters
5.1 Southern Region
5.1.1 Andhra Pradesh - The Hyderabad Bio-Cluster
5.1.2 Karnataka - The Bangalore Bio-Cluster
5.1.3 Tamil Nadu - The Chennai Bio-Cluster
5.1.4 Kerala
5.2 Western Region
5.2.1 Maharashtra - The Pune Bio-Cluster
5.2.2 Gujarat
5.3 Northern Region
5.3.1 Uttar Pradesh - Lucknow
5.3.2 Punjab
6. Industry Analysis
6.1 Key Driving Forces
6.1.1 Human Resources
6.1.2 Strong Bio-processing Skills
6.1.3 Bio-diversity
6.1.4 Regulatory Framework
6.2 Opportunity
6.2.1 Outsourcing of Preliminary Research
6.2.2 Off-patent Drug
6.2.3 Clinical Trial Opportunity
6.2.4 Bioinformatics
6.2.5 Stem Cell Research
6.2.6 Agricultural Biotechnology
6.2.7 Biofuel
6.2.8 Biofertilizers/BioPesticides
6.3 Challenges
6.3.1 Lack of IPR (Intellectual Property Rights) Regime
6.3.2 Time to Market
6.3.3 Seed Funding
6.3.4 Synergy between Stakeholders
6.3.5 High Innovative Drug Cost
6.3.6 Regulatory Issues
6.4 Future Outlook, 2010
7. Key Players and Company Profiles
7.1 Biotech Suppliers
7.2 Biotech Companies
7.3 Company Profiles
7.3.1 Biocon
7.3.2 Serum Institute of India
7.3.3 Panacea Biotech
7.3.4 Nicholas Piramal India Limited (NPIL)
7.3.5 Wockhardt Limited
7.3.6 GlaxoSmithKline
7.3.7 Bharat Serums and Vaccines (BSV)
7.3.8 Krebs Biochemical’s & Industries Limited (KBIL)
7.3.9 Zydus Cadila
7.3.10 Indian Immunologicals Limited (IIL)
7.3.11 Shantha Biotechnics
7.3.12 Biological E
7.3.13 Chiron Behring Vaccines
7.3.14 Eli Lilly
7.3.15 Novo Nordisk
7.3.16 Mahyco Monsanto
7.3.17 Bharat Biotech
7.3.18 Abbott
7.3.19 Ranbaxy
7.3.20 Novozymes
8. Annexure I: Government Initiatives and Regulations
8.1 Fiscal Incentives Provided to the Biotech Sector
8.1.1 Tax
8.1.2 Regulatory
8.1.3 Investment
8.2 Important Changes to the Patents Act in the Third Amendment Bill
8.2.1 Substantive Changes
8.2.1.1 Introduction of Product Patent Protection in All Fields of Technology
8.2.1.2 Deletion of Provisions Relating to Exclusive Marketing Rights
8.2.1.3 Compulsory License to Supply Drugs to Help Needy Countries
8.2.2 Procedural Changes
8.2.2.1 Expansion of Jurisdiction of the Appellate Tribunal
8.3 Plant Varieties and Farmers’ Rights Protection Act, 2001
8.4 Other Regulations impacting the Biotech Sector
8.4.1 Licensing
8.4.2 Clinical Trials
8.4.3 Seeds Act and Policy
8.4.4 Environmental Clearances
8.4.5 Biological Diversity Act
.jpg)
